Cargando…

Analysis of COVID-19-Associated Proteins Identifies TANK-Binding Kinase 1 As an Immunotherapeutic Target in Multiple Myeloma

Detalles Bibliográficos
Autores principales:	Ray, Arghya, DU, Ting, Chauhan, Krishan, Chauhan, Dharminder, Anderson, Kenneth C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology. Published by Elsevier Inc. 2022
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665253/ http://dx.doi.org/10.1182/blood-2022-170226

Ejemplares similares

Analysis of Sars-Cov-2-Associated Proteins Identify Tank-Binding Kinase-1 As an Immunotherapeutic Target in Multiple Myeloma
por: Ray, Arghya, et al.
Publicado: (2020)

Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma
por: Ray, Arghya, et al.
Publicado: (2022)

Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity
por: Ray, Arghya, et al.
Publicado: (2019)

Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13
por: Song, Yan, et al.
Publicado: (2021)

Targeting the UPS as therapy in multiple myeloma
por: Chauhan, Dharminder, et al.
Publicado: (2008)

A Novel Hypoxia-Selective Epigenetic Agent RRx-001 Triggers Apoptosis and Overcomes Drug Resistance in Multiple Myeloma Cells
por: Das, Deepika Sharma, et al.
Publicado: (2016)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
por: Nadeem, Omar, et al.
Publicado: (2020)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

P822: EPIGENETIC REGULATION OF CD155 ON MULTIPLE MYELOMA CELLS INFLUENCES ANTI-TUMOR NOVEL IMMUNOTHERAPEUTIC APPROACHES
por: Martinez-Verbo, Laura, et al.
Publicado: (2023)

Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas
por: Chauhan, Dharminder, et al.
Publicado: (2011)

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients
por: Levin, Nancy, et al.
Publicado: (2016)

Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
por: Meyers, Daniel E., et al.
Publicado: (2017)

Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
por: Swan, Dawn, et al.
Publicado: (2019)

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
por: Morandi, Fabio, et al.
Publicado: (2018)

Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma
por: Frede, Julia, et al.
Publicado: (2021)

Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?
por: Cooke, Rachel E., et al.
Publicado: (2019)

Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
por: Swamydas, Muthulekha, et al.
Publicado: (2022)

Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma
por: Fang, Yi, et al.
Publicado: (2021)

SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
por: Chu, Emily, et al.
Publicado: (2023)

TANK-Binding Kinase 1-Dependent Responses in Health and Autoimmunity
por: Louis, Cynthia, et al.
Publicado: (2018)

1327. Human Rhinovirus Infection in Multiple Myeloma Patients: Effect on Morbidity and Mortality
por: Hasan, Lana, et al.
Publicado: (2021)

Multiple Myeloma
Publicado: (2019)

Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
por: Suzuki, Rikio, et al.
Publicado: (2014)

Tank binding kinase 1 is a centrosome-associated kinase necessary for microtubule dynamics and mitosis
por: Pillai, Smitha, et al.
Publicado: (2015)

Glyphosate Efficacy in Chloris virgata Sw. in Response to Temperature and Tank Mixing
por: Mahajan, Gulshan, et al.
Publicado: (2022)

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry
por: Richter, Joshua, et al.
Publicado: (2022)

Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
por: Favreau, Mérédis, et al.
Publicado: (2016)

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
por: Kostopoulos, Ioannis V., et al.
Publicado: (2020)

UPAR AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN RECURRENT GLIOBLASTOMA
por: Maich, William, et al.
Publicado: (2023)

Comparative In Silico Analysis and Functional Characterization of TANK-Binding Kinase 1–Binding Protein 1
por: Sawal, Humaira Aziz, et al.
Publicado: (2023)

Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
por: Branagan, Andrew R., et al.
Publicado: (2022)

Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination
por: Kogan Zajdman, Ariel, et al.
Publicado: (2022)

P811: PIM2 KINASE REGULATES TIGIT EXPRESSION AND ENERGY METABOLISM IN NK CELLS OF PATIENTS WITH MULTIPLE MYELOMA
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Knockdown of TANK-Binding Kinase 1 Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular-Targeted Drugs
por: Du, Fengxia, et al.
Publicado: (2022)

17. A Retrospective Cohort Study of Influenza Infected Multiple Myeloma Patients Comparing Clinical Outcomes Between Vaccinated and Unvaccinated
por: Wilson, Taylor D, et al.
Publicado: (2021)

The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance
por: Ferguson, Ian D., et al.
Publicado: (2022)

P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic
por: Lykopoulos, K, et al.
Publicado: (2014)

Shifts in Multiple Myeloma Care Utilization of Veterans in the COVID-19 Era: Interrupted Time Series Analysis of Veterans Health Administration Data
por: Su, Christopher T, et al.
Publicado: (2022)

ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors
por: Orentas, Rimas J, et al.
Publicado: (2013)

P-115: Unc-51 Like Kinase 3 protein (ULK3)-mediated autophagy is responsible for multiple myeloma resistance to chemotherapy
por: Tauro, Marilena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_beuic3a2hkaefsk1phpuhrv73s